Allurion Technologies
ALUR

$0.6250

2.46%

Market Cap: $40.2M

About: Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Employees: 24

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

19% more funds holding

Funds holding: 27 [Q1] → 32 (+5) [Q2]

5.84% more ownership

Funds ownership: 15.86% [Q1] → 21.7% (+5.84%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

22% less capital invested

Capital invested by funds: $13.3M [Q1] → $10.3M (-$2.95M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

220%

upside

Avg. target

$2.25

260%

upside

High target

$2.50

300%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Roth MKM Jason Wittes 71% 1-year accuracy 12 / 17 met price target	220%upside $2	Buy Initiated	6 Sept 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 18 / 47 met price target	300%upside $2.50	Buy Maintained	22 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ALUR published over the past 30 days

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Averag.

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. “I believe having Keith as a sou.

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program's ongoing virtual guidance and support. In the study, 486.

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Receives Continued Listing Standards Notice from NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE's continued listing standards because the average closing price of the Company's common stock per the Notice was less than $1.00 per share over the consecutive 30 trading-day period ended August 8, 2024.

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR ) Q2 2024 Earnings Call Transcript August 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Shantanu Gaur - Founder and CEO Chris Geberth - CFO Conference Call Participants Keay Nakae - Chardan Matt Taylor - Jefferies Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. Recent Company Highlights Second quarter revenue of $11.8 million, a sequential increase of $2.4 million or 25% from the first quarter of 2024 Second quarter loss from operations reduced by 30% compared to the year-ago period and by 44% when o.

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase 14,406,508 Shares (the “Warrants” and, together with the Shares, the “Securities”) at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before de.

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

Allurion Announces Launch of Offering of Common Stock and Warrants

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.

Allurion Announces Launch of Offering of Common Stock and Warrants

Why Is Allurion (ALUR) Stock Up 140% Today?

Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name.

Why Is Allurion (ALUR) Stock Up 140% Today?

See News Rankings